Scribe Therapeutics Inc. SCTX
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -14.11% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -14.11% | ||||
| Cost of Revenue | -21.95% | ||||
| Gross Profit | 23.89% | ||||
| SG&A Expenses | -25.78% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -22.83% | ||||
| Operating Income | 24.40% | ||||
| Income Before Tax | 63.40% | ||||
| Income Tax Expenses | -7.02% | ||||
| Earnings from Continuing Operations | 62.66% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 62.66% | ||||
| EBIT | 24.40% | ||||
| EBITDA | 25.76% | ||||
| EPS Basic | 62.89% | ||||
| Normalized Basic EPS | 26.21% | ||||
| EPS Diluted | 62.89% | ||||
| Normalized Diluted EPS | 26.21% | ||||
| Average Basic Shares Outstanding | 0.61% | ||||
| Average Diluted Shares Outstanding | 0.61% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||